Post-market review of ezetimibe - final report

PBAC

20 December 2017 - The final report for the post-market review of ezetimibe and PBAC recommendations for the post-market review of ezetimibe have been published on the PBS website.

The report, including PBAC sub-committee advice and stakeholder comments, was provided to the PBAC for consideration in July 2017.

The PBAC agreed that an Authority Required (Streamlined) listing remained the most appropriate restriction to maintain ezetimibe’s place as second-line therapy. This restriction is consistent with clinical guidelines and serves to direct use to the high- risk population who will derive most benefit from ezetimibe therapy.

The PBAC made a number of other recommendations in its advice to the Minister. These included the removal of the General Statement on Lipid Lowering Drugs, due to its inconsistency with current guidelines and Quality Use of Medicine initiatives to ensure optimal first line initiation and gradual increase of statin therapy to maximally tolerated doses.

Read Final Report

Michael Wonder

Posted by:

Michael Wonder